Ironwood Pharmaceuticals Announces Upcoming Presentations at Jefferies Global Healthcare Conference and Goldman Sachs Annu

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present at the Jefferies 2011 Global Healthcare Conference on Monday, June 6, 2011 at 11:30 a.m. Eastern Time at the Grand Hyatt in New York City. Ironwood will also present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time at the Terranea Resort in Rancho Palos Verdes, Calif.

A live webcast of each Ironwood presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be required. A replay of each webcast will be available on Ironwood’s website for 14 days following each conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonist, is in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotide’s development program has been completed and will support the NDA submission for both indications, as well as the MAA submission for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.



CONTACT:

Ironwood Pharmaceuticals
Susan Brady, 617-621-8304
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.